InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China
BEIJING, Sept. 08, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the